Comparative Pharmacology
Head-to-head clinical analysis: HALCION versus MENRIUM 10 4.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALCION versus MENRIUM 10 4.
HALCION vs MENRIUM 10-4
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Triazolam is a benzodiazepine that enhances the effect of GABA at the GABA-A receptor, increasing chloride ion conductance and causing neuronal hyperpolarization, leading to CNS depression.
Mennium 10-4 is a combination of chlordiazepoxide, a benzodiazepine that enhances GABA-A receptor activity, and clidinium, an antimuscarinic that blocks muscarinic acetylcholine receptors.
0.25 mg orally once daily at bedtime, maximum 0.5 mg per day.
Adults: 1 tablet (chlordiazepoxide 10 mg / clidinium 4 mg) orally 3 to 4 times daily before meals and at bedtime. Max: 4 tablets per day.
None Documented
None Documented
Terminal elimination half-life is 1.5–5.5 hours (mean 2.5 hours). Short half-life minimizes next-day sedation.
Chlordiazepoxide: 5-30 h (mean 20 h); clidinium: 10-20 h. Steady-state reached in 5-7 days.
Primarily renal (80%) as conjugated metabolites; fecal (8%); unchanged drug <1%.
Renal (60% as unchanged chlordiazepoxide, 15% as conjugated metabolites; 5% biliary/fecal as metabolites)
Category C
Category C
Benzodiazepine
Benzodiazepine/Estrogen Combination